MTOR and cervical carcinoma: The present observation is supported by two studies on primary cervical cancer: Faried et al. reported increased p-mTOR expression to be associated with impaired survival in 25 advanced cervical cancers undergoing cisplatin-based neoadjuvant chemotherapy [39].